Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials
Neurological Sciences · 2024-07 · 45 (7) · 3503-3507
DOI: 10.1007/s10072-024-07502-y ↗Kurz gefasst
Metaanalyse in der Zeitschrift Neurological Sciences, online erschienen am 17.04.2024. Verfasst von Abdullah Ashraf Hamad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Menoufia University, Menoufia, Egypt. Abdullah.hamad744@gmail.com. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Thiazoles, Neurodegenerative Diseases, Piperidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Science, Technology & Innovation Funding Authority.
Abstract (Originalsprache)
Objectives
This meta-analysis aimed to examine the safety of masitinib in patients with neurodegenerative diseases.
Methods
We considered randomized controlled trials (RCTs) comparing different doses of masitinib versus placebo. We performed our analysis using the R (v.4.3.0) programming language and the incidence of adverse events was pooled using risk ratio (RR) and 95% confidence interval (CI).
Results
We included five RCTs, focusing on multiple sclerosis (MS), Alzheimer's disease (AD), and amyotrophic lateral sclerosis. The meta-analysis revealed a significantly higher incidence of adverse events in the masitinib group compared to the control group, regardless of adverse event grade and masitinib dose (RR = 1.12, 95% CI [1.07 to 1.17], P < 0.01). Adverse events categorized as severe, non-fatal serious, leading to dose reduction, and leading to permanent discontinuation also showed a higher incidence in the masitinib group ( P ≤ 0.01). Subgroup analysis for AD and MS supported these findings. The pooled incidence of adverse events, regardless of their grade, was higher in the masitinib group for both the 3 mg/kg/d dose (RR = 1.13, P = 0.01) and the 4.5 mg/kg/d dose (RR = 1.11, P < 0.01). However, there was no significant difference between masitinib 3 mg/kg/d dose and placebo regarding severe and non-fatal serious adverse events for the.
Conclusion
Masitinib use in neurodegenerative diseases presents safety concerns that may impact patients' quality of life and require management. Further research is recommended to determine the optimal dose with minimal safety concerns in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Menoufia University, Menoufia, Egypt. Abdullah.hamad744@gmail.com.
- Faculty of Medicine, Benha University, Benha, Egypt.
- Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA.
Förderung
- The Science, Technology & Innovation Funding Authority
Zitieren
APA
Hamad, A. A., & Amer, B. E. (2024). Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials. Neurological Sciences, 45(7), 3503-3507. https://doi.org/10.1007/s10072-024-07502-y
Vancouver
Hamad AA, Amer BE. Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials. Neurological Sciences. 2024;45(7):3503-3507. doi:10.1007/s10072-024-07502-y
BibTeX
@article{Hamad2024,
author = {Hamad, Abdullah Ashraf and Amer, Basma Ehab},
title = {Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials},
journal = {Neurological Sciences},
year = {2024},
volume = {45},
number = {7},
pages = {3503--3507},
doi = {10.1007/s10072-024-07502-y}
}
EUVIMED